OncoCyte’s DetermaIO predicts response to Atezolizumab in Phase 2 trial

Oncocyte announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO. The NeoTRIP Phase 2 clinical trial randomized patients with triple-negative breast cancer, TNBC, to receive neoadjuvant carboplatin and nab-paclitaxel, with or without the immunotherapy, atezolizumab. As a secondary point of interest in the study, Oncocyte’s DetermaIO test was among several established biomarkers and gene signatures assessed for its ability to predict which patients with early stage TNBC are most likely to benefit from the immunotherapy. The study was performed in collaboration with the Michelangelo Foundation for Cancer Research, a well-regarded independent scientific organization based in Milan. Only DetermaIO was both statistically significant and predictive of a pathologic complete response among the various biomarkers assessed.